Search

Author/Creator Taube, Tillmann

1. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. (19th November 2018)

Authors:
Döhner, Hartmut; Müller‐Tidow, Carsten; Lübbert, Michael; Fiedler, Walter; Krämer, Alwin; Westermann, Jörg; Bug, Gesine; Schlenk, Richard F.; Krug, Utz; Goeldner, Rainer‐Georg; Hilbert, James; Taube, Tillmann; Ottmann, Oliver G.
Journal:
British journal of haematology
Issue:
Volume 185:Number 3(2019)
Page Start:
583
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized, open‐label, phase I/II trial to investigate the maximum tolerated dose of the Polo‐like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. (16th August 2013)

Authors:
Müller‐Tidow, Carsten; Bug, Gesine; Lübbert, Michael; Krämer, Alwin; Krauter, Jürgen; Valent, Peter; Nachbaur, David; Berdel, Wolfgang E.; Ottmann, Oliver G.; Fritsch, Holger; Munzert, Gerd; Garin‐Chesa, Pilar; Fleischer, Frank; Taube, Tillmann; Döhner, Hartmut
Journal:
British journal of haematology
Issue:
Volume 163:Number 2(2013:Oct.)
Page Start:
214
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. Issue 8 (2nd August 2021)

Authors:
Döhner, Hartmut; Symeonidis, Argiris; Deeren, Dries; Demeter, Judit; Sanz, Miguel A.; Anagnostopoulos, Achilles; Esteve, Jordi; Fiedler, Walter; Porkka, Kimmo; Kim, Hee-Je; Lee, Je-Hwan; Usuki, Kensuke; D'Ardia, Stefano; Won Jung, Chul; Salamero, Olga; Horst, Heinz-August; Recher, Christian; Rous...
Journal:
HemaSphere
Issue:
Volume 5:Issue 8(2021)
Page Start:
e617
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Phase I dose‐escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Issue 10 (5th July 2019)

Authors:
Doz, François; Locatelli, Franco; Baruchel, André; Blin, Nicolas; De Moerloose, Barbara; Frappaz, Didier; Dworzak, Michael; Fischer, Matthias; Stary, Jan; Fuertig, Rene; Riemann, Kathrin; Taube, Tillmann; Reinhardt, Dirk
Journal:
Pediatric blood & cancer
Issue:
Volume 66:Issue 10(2019)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. (8th June 2018)

Authors:
Ottmann, Oliver G.; Müller‐Tidow, Carsten; Krämer, Alwin; Schlenk, Richard F.; Lübbert, Michael; Bug, Gesine; Krug, Utz; Bochtler, Tilmann; Voss, Florian; Taube, Tillmann; Liu, Dan; Garin‐Chesa, Pilar; Döhner, Hartmut
Journal:
British journal of haematology
Issue:
Volume 184:Number 6(2019)
Page Start:
1018
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia. Issue 11 (21st October 2015)

Authors:
Kobayashi, Yukio; Yamauchi, Takahiro; Kiyoi, Hitoshi; Sakura, Toru; Hata, Tomoko; Ando, Kiyoshi; Watabe, Aiko; Harada, Akiko; Taube, Tillmann; Miyazaki, Yasushi; Naoe, Tomoki
Journal:
Cancer science
Issue:
Volume 106:Issue 11(2015:Nov.)
Page Start:
1590
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗